サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1772236

ロザノリキシズマブ（Rystiggo）の世界市場：市場規模・シェア・動向分析 (適応症別・流通チャネル別・地域別)、セグメント別予測 (2025年～2033年)

Rozanolixizumab (Rystiggo) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Emerging Pipeline Applications), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
ロザノリキシズマブ（Rystiggo）の世界市場：市場規模・シェア・動向分析 (適応症別・流通チャネル別・地域別)、セグメント別予測 (2025年～2033年)
出版日: 2025年06月26日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ロザノリキシズマブ（Rystiggo）市場サマリー

世界のロザノリキシズマブ（Rystiggo）の市場規模は、2024年に2億1,861万米ドルと推定され、2025年から2033年にかけて15.22%のCAGRで成長し、2033年には17億40万米ドルに達すると予測されます。慢性尋常性乾癬と関節症性乾癬の有病率の増加は、高度生物学的製剤の需要を拡大させています。

重症汎発性筋無力症（gMG）に対する承認が市場を牽引します。国際的な動向としては、標的治療薬に対する需要の高まりや、承認取得の可能性や医療アクセスの増加に後押しされた世界の規制当局の承認が挙げられます。UCBの革新的なアプローチと新たなパイプラインが成長を支えています。ロザノリキシズマブ（Rystiggo）市場は、慢性的な自己免疫疾患であるgMGを標的としており、有病率の増加が需要を牽引しています。米国と欧州で承認されたRystiggoは皮下投与が可能で、IgG抗体を減少させる効果があるため、採用に拍車をかけています。市場の成長は、診断率の上昇と自己免疫疾患に罹患しやすい高齢化によって促進されます。UCBは適応症の拡大に注力しており、2033年までにはさらに増加すると予測されています。

Rystiggoの主な利点は、新規のFcRn標的メカニズムにあり、MycarinG試験で実証されたように、嚥下や呼吸などのgMG症状の大幅な改善をもたらします。血漿交換と比較して、有効性を維持しながら副作用を軽減することができます。皮下投与は患者の利便性を高め、静脈内投与の競合薬に対して有利な位置づけとなります。

新たなイノベーションとしては、慢性炎症性脱髄症候群（CIDP）に対する試験や自己投与法があります。パイプラインの拡充に成功すれば、2033年までに対処可能な市場が倍増する可能性があります。送達システムの進歩はコンプライアンス向上を目指すものであり、バイオシミラーの可能性は長期的にコストとアクセシビリティのバランスを取りながら競争をもたらす可能性があります。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 ロザノリキシズマブ（Rystiggo）市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 ロザノリキシズマブ（Rystiggo）市場：適応症別のビジネス分析

  • 市場シェア：適応症別（2024年・2033年）
  • セグメントダッシュボード：適応症別
  • 市場規模の予測と動向分析：適応症別（2021年～2033年）
  • 全身性重症筋無力症（gMG）
  • その他

第5章 ロザノリキシズマブ（Rystiggo）市場：流通チャネルのビジネス分析

  • 市場シェア：流通チャネル別（2024年・2033年）
  • セグメントダッシュボード：流通チャネル別
  • 市場規模の予測と動向分析：流通チャネル別（2021年～2033年）
  • 病院・専門薬局
  • 小売・eコマース

第6章 ロザノリキシズマブ（Rystiggo）市場：地域別の推定・動向分析

  • 市場シェア：地域別（2024年・2033年）
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析：地域別（2021年～2033年）
  • 北米
    • 国別（2021年～2033年）
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参入企業の概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • UCB
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Rozanolixizumab (Rystiggo) market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 5. Global Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 8. North America Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 10. U.S. Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 12. Canada Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 14. Mexico Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 17. Europe Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 19. UK Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 21. Germany Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 23. France Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 25. Italy Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 27. Spain Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 29. Norway Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 31. Denmark Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 33. Sweden Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37. Japan Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 38. Japan Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 40. China Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 42. India Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 44. Australia Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 46. South Korea Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 48. Thailand Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 51. Latin America Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 53. Brazil Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 55. Argentina Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 60. South Africa Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 64. UAE Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Rozanolixizumab (Rystiggo) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Rozanolixizumab (Rystiggo) market dynamics
  • Fig. 12 Rozanolixizumab (Rystiggo) market: Porter's five forces analysis
  • Fig. 13 Rozanolixizumab (Rystiggo) market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
  • Fig. 16 Emerging Pipeline Applications market, 2021 - 2033 (USD Million)
  • Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 18 Hospital & Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 19 Retail & E-Commerce market, 2021 - 2033 (USD Million)
  • Fig. 20 Rozanolixizumab (Rystiggo) market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 North America Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 29 Europe Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 30 UK country dynamics
  • Fig. 31 UK Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 32 Germany country dynamics
  • Fig. 33 Germany Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 34 France country dynamics
  • Fig. 35 France Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 36 Italy country dynamics
  • Fig. 37 Italy Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 38 Spain country dynamics
  • Fig. 39 Spain Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway country dynamics
  • Fig. 41 Norway Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden country dynamics
  • Fig. 43 Sweden Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 44 Denmark country dynamics
  • Fig. 45 Denmark Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 46 Asia Pacific Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 47 Japan country dynamics
  • Fig. 48 Japan Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 49 China country dynamics
  • Fig. 50 China Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 51 India country dynamics
  • Fig. 52 India Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 53 Australia country dynamics
  • Fig. 54 Australia Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 55 South Korea country dynamics
  • Fig. 56 South Korea Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil country dynamics
  • Fig. 61 Brazil Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina country dynamics
  • Fig. 63 Argentina Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 64 MEA Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 65 South Africa country dynamics
  • Fig. 66 South Africa Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 67 Saudi Arabia country dynamics
  • Fig. 68 Saudi Arabia Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 69 UAE country dynamics
  • Fig. 70 UAE Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 71 Kuwait country dynamics
  • Fig. 72 Kuwait Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 73 Company categorization
  • Fig. 74 Company market position analysis
  • Fig. 75 Strategic framework
目次
Product Code: GVR-4-68040-644-4

Rozanolixizumab (Rystiggo) Market Summary

The global rozanolixizumab (Rystiggo) market size was estimated at USD 218.61 million in 2024 and is projected to reach USD 1,700.40 million by 2033, growing at a CAGR of 15.22% from 2025 to 2033. The increasing prevalence of chronic plaque psoriasis and psoriatic arthritis drives greater demand for advanced biologic therapies.

The market is driven by its approval for generalized myasthenia gravis (gMG). Key trends include rising demand for targeted therapies and global regulatory approvals, fueled by potential approvals and increasing healthcare access. Growth is supported by UCB's innovative approach and emerging pipeline applications. The rozanolixizumab (Rystiggo) market targets gMG, a chronic autoimmune disorder, with growing prevalence driving demand. Approved in the U.S. and Europe, Rystiggo's subcutaneous administration and efficacy in reducing IgG antibodies fuel its adoption. Market growth is propelled by rising diagnosis rates and an aging population susceptible to autoimmune diseases. UCB's focus on expanding indications further supports the projected increase by 2033.

Rystiggo's key advantage lies in its novel FcRn-targeting mechanism, offering significant improvements in gMG symptoms like swallowing and breathing, as demonstrated in the MycarinG study. Compared to plasma exchange, it reduces side effects while maintaining efficacy. Its subcutaneous delivery enhances patient convenience, positioning it favorably against intravenous competitors.

Emerging innovations include trials for chronic inflammatory demyelinating syndrome (CIDP) and self-administration methods. Successful pipeline expansion could double the addressable market by 2033. Advances in delivery systems aim to improve compliance, while potential biosimilars may introduce competition, balancing cost and accessibility in the long term.

Global Rozanolixizumab (Rystiggo) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rozanolixizumab (Rystiggo) market report based on indication, distribution channel and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Generalized Myasthenia Gravis (gMG)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital & Specialty Pharmacies
  • Retail & E Commerce
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Generalized Myasthenia Gravis (gMG)
    • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital & Specialty Pharmacies
    • 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail & E-Commerce
    • 5.5.1. Retail & E-Commerce Market, 2021 - 2033 (USD Million)

Chapter 6. Rozanolixizumab (Rystiggo) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Rozanolixizumab (Rystiggo) Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives